Skip to main content

Table 2 Demographic and Clinical Characteristics of Patients with AD

From: Effects of variations in access to care for children with atopic dermatitis

 

Medicaid

n = 268,580

Commercial

n = 338,678

P-value

Demographics

 Age, mean ± SD | median

5.1 ± 4.9 | 4.0

5.6 ± 5.2 | 4.0

<0.001*

Age category, n (%)

 0–1 yr

89,336 (33.3)

106,255 (31.4)

<0.001*

 2–5 yr

69,980 (26.1)

82,290 (24.3)

<0.001*

 6–11 yr

73,713 (27.4)

91,400 (27.0)

<0.001*

 12–17 yr

35,551 (13.2)

58,733 (17.3)

<0.001*

Male, n (%)

133,153 (49.6)

174,839 (51.6)

<0.001*

Comorbidities during the 6-month baseline perioda

Patients with ≥1 selected comorbidity, n (%)

144,397 (53.8)

144,707 (42.7)

<0.001*

 Patients with ≥1 atopic comorbidity, n (%)

89,077 (33.2)

88,135 (26.0)

<0.001*

  Allergic conjunctivitis

20,170 (7.5)

22,235 (6.6)

<0.001*

  Allergic rhinitis

54,665 (20.4)

50,872 (15.0)

<0.001*

  Allergic urticaria

1762 (0.7)

3036 (0.9)

<0.001*

  Asthma

40,313 (15.0)

33,038 (9.8)

<0.001*

  Chronic rhinosinusitis

4593 (1.7)

5100 (1.5)

<0.001*

  Eosinophilic esophagitis

140 (0.1)

331 (0.1)

<0.001*

  Food allergy

2928 (1.1)

6644 (2.0)

<0.001*

  Nasal polyps

65 (0.0)

94 (0.0)

0.395

Patients with ≥ 1 other selected comorbidity, n (%)

82,491 (30.7)

75,381 (22.3)

<0.001*

 Anxiety

2890 (1.1)

3724 (1.1)

0.380

 Attention deficit hyperactivity disorder

13,802 (5.1)

6176 (1.8)

<0.001*

 Autoimmune disorders

870 (0.3)

1050 (0.3)

0.338

 Bacterial infections

8417 (3.1)

11,590 (3.4)

<0.001*

 Depression

4474 (1.7)

2330 (0.7)

<0.001*

 Fungal infections

46,418 (17.3)

33,992 (10.0)

<0.001*

 Obesity

7382 (2.7)

2875 (0.8)

<0.001*

 Sleep disorders

1138 (0.4)

444 (0.1)

<0.001*

 Viral infections and disorders

13,350 (5.0)

23,506 (6.9)

<0.001*

Provider type on the index visit, n (%)

 Dermatology

8545 (3.2)

63,354 (18.7)

<0.001*

  Subsequent dermatology or A/I visit after the index visitb, n (%)

4523 (52.9)

28,523 (45.0)

<0.001*

 Allergy/Immunology

7612 (2.8)

31,626 (9.3)

<0.001*

  Subsequent dermatology or A/I visit after the index visitb, n (%)

4011 (52.7)

16,050 (50.7)

0.002*

 Pediatrics

67,333 (25.1)

166,009 (49.0)

<0.001*

  Subsequent dermatology or A/I visit after the index visitb, n (%)

6667 (9.9)

24,849 (15.0)

<0.001*

 Other

185,090 (68.9)

77,689 (22.9)

<0.001*

  Subsequent dermatology or A/I visit after the index visitb, n (%)

3752 (2.0)

9392 (12.1)

<0.001*

Patients who received ≥ 1 AD treatment during the observation periodc, n (%)

240,648 (89.6)

236,836 (69.9)

<0.001*

Duration of observation period (months), mean ± SD | median

36.4 ± 16.7 | 34.4

31.3 ± 15.3 | 27.6

<0.001*

  1. Notes
  2. AD atopic dermatitis, SD standard deviation, A/I allergist/immunologist
  3. aThe baseline period includes the index date. For infants, the baseline period includes up to 6 months of follow-up
  4. bPercentages calculated out of the total number of patients with each provider type on the index date
  5. cPatients considered in the analysis of treatment patterns
  6. *P-value <0.05. P-values were calculated using Chi-square tests for categorical variables, and Wilcoxon Mann-Whitney test for continuous variables
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us